The market size of the global genome editing will be estimated at USD 11.2 billion in 2025 and is expected to grow to between USD 13.1 billion in 2026 and about USD 55.7 billion by 2035 with a current CAGR of 17.4% during the period of 2026 to 2035.
Genome Editing Market Revenue and Trends
Genome editing refers to a collection of sophisticated biotechnological techniques that allow for the precise alteration of an organism's DNA by either adding or removing specific genetic sequences or changing them. Scientists are capable of manipulating genes accurately and efficiently through the use of molecular tools, for example, CRISPR systems, which allow them to make controlled mutations in the exact places within the genome.
The applications of genome editing are very diverse, covering areas of biomedical research, therapeutic development, agriculture, and industrial biotechnology, where it supports such activities as disease modeling, targeted treatment development, crop improvement, and optimization of biological processes. The capacity to perform specific and predictable genetic modifications has made genome editing a core technology that enables the life science sector to keep coming up with new ideas.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the Genome Editing Market?
The clinical need and the broadening of indications are the main factors fueling the genome editing market. The rising demand for genetic, rare, and complex diseases with limited therapeutic options is a key factor behind this. The application of genome editing technologies looks forward to one-time or durable treatments as it conducts a direct correction of disease-causing genetic mutations. Therefore, they are considered very suitable for such conditions as inherited blood disorders, rare genetic syndromes, cancers, and some neurological diseases.
The development of research is taking the use of genome editing in the treatment of diseases further and further, as it is now reaching the area of chronic conditions and more common diseases, thus increasing both the clinical and the commercial sides of its use. The potential use for treating such a wide variety of conditions further fortifies the demand from hospitals, laboratories, and pharmaceutical companies, which in turn fastens the growth of the market and the acceptance of the technology.
Segment Insight
By Delivery Method
The in vivo segment is growing at a significant rate over the projected period. One of the factors that contributed most heavily to the growth of the market is the adoption and expansion of gene editing delivery methods such as the application of special vectors and the implementation of non-viral techniques. The introduction of these methods has opened up new avenues for treating hereditary disorders, neoplasms, and non-therapeutic areas by providing a safe and reliable way of performing gene edits within living organisms. The pipeline of in vivo clinical trials and the occurrences of proof-of-concept are constantly pouring into the market, which slowly but surely leads to the build-up of investments, regulators' scrutiny, and payers' trust in these methods. All these components not only grow the market but also propel the revenue from in vivo gene editing, which is a part of the overall gene editing market, to reach greater heights besides the commercial potentials that are opened up by the new technology.
By Application
The genetic engineering segment is growing at a significant rate over the projected period. Genetic engineering is the light cutting-edge technology where genome-editing systems are the main instruments for a wide range of applications. The growth in the needs for genes, cells, and organisms made by humans through medical and cosmetic means and biotechnology in agriculture and industry has made the precise modification of DNA through genome editing one of the key factors driving commercial use and increasing market sales, thus, the role of genome editing is getting bigger. Tools for editing the genome, including CRISPR, TALENs, and other platforms, are being applied more and more to create new therapeutics, disease models, crops with high yields or resistance to stress, and strains for biological production that are optimized, and this is the root of investment and gene editing services and products’ adoption. The ever-growing dependence on genome editing for a variety of genetic engineering tasks brings the genetic engineering and genome editing markets closer together in terms of revenue growth.
Regional Insights
The genome editing market has been dominated by North America. The presence of major players and heavy investment in R&D drive the market growth. Moreover, the rising prevalence of chronic disease drives the market growth.
Besides, the Asia Pacific market has the highest rate of growth in the genome editing market. The growing investment in healthcare infrastructure and increasing number of startups in the area.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 13.1 billion |
Projected Market Size in 2035 | USD 55.7 billion |
Market Size in 2025 | USD 11.2 billion |
CAGR Growth Rate | 17.4% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Technology, Delivery Method, Application, Mode, End Use and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In July 2025, Global genomics leader Integrated DNA Technologies (IDT) is changing the game in the field of translational gene editing by introducing new products in its all-inclusive CRISPR portfolio. The company’s expanded solutions for CRISPR translational research are made to aid researchers in speeding up the process of developing more CRISPR-based treatments for patients such as KJ Muldoon, an infant with CPS1 deficiency who, thanks to the world’s first personalized CRISPR therapy produced by IDT and Aldevron, is now able to enjoy life. IDT was responsible for the guide RNA (gRNA), performed off-target analysis and provided regulatory support for baby KJ’s treatment which was done in an incredibly fast timeline. (Source: https://www.idtdna.com/pages/about/news/2025/07/16/integrated-dna-technologies-announces-translational-crispr-portfolio-expansion-with-product-innovation-updates)
List of the prominent players in the Genome Editing Market:
Genome Medical Inc.
Editas Medicine
Illumina Inc.
Tecan Trading AG
Precision Biosciences
PerkinElmer Inc.
Cellectis S.A
Lonza
BioMed Central Ltd
Aevi Genomic Medicine Inc.
Congenica Ltd.
Deep Genomics
Editas Medicine
CRISPR Therapeutics
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Agilent Technologies Inc.
Others
The Genome Editing Market is segmented as follows:
By Technology
CRISPR)/Cas9
TALENs/MegaTALs
Meganucleases
ZFN
Others
By Delivery Method
Ex-vivo
In-vivo
By Application
Cell Line Engineering
Diagnostic Applications
Genetic Engineering
Drug Discovery and Development
Other Applications
By Mode
Contract
In-house
By End Use
Biotechnology and pharmaceutical companies
Contract research organizations
Academic and government research institutes
Regional Coverage:
North America
U.S.
Canada
Mexico
Rest of North America
Europe
Germany
France
U.K.
Russia
Italy
Spain
Netherlands
Rest of Europe
Asia Pacific
China
Japan
India
New Zealand
Australia
South Korea
Taiwan
Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
